Cargando…

Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme

PURPOSE: Health-related quality of life (HRQOL) in differentiated thyroid cancer (DTC) research has so far received little attention and available results are conflicting. We studied the HRQOL of radioiodine-naive DTC patients in comparison with the general population (GP), investigated the course o...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamper, Eva-Maria, Wintner, Lisa M., Rodrigues, Margarida, Buxbaum, Sabine, Nilica, Bernhard, Singer, Susanne, Giesinger, Johannes M, Holzner, Bernhard, Virgolini, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480943/
https://www.ncbi.nlm.nih.gov/pubmed/25771905
http://dx.doi.org/10.1007/s00259-015-3022-9
_version_ 1782378215783792640
author Gamper, Eva-Maria
Wintner, Lisa M.
Rodrigues, Margarida
Buxbaum, Sabine
Nilica, Bernhard
Singer, Susanne
Giesinger, Johannes M
Holzner, Bernhard
Virgolini, Irene
author_facet Gamper, Eva-Maria
Wintner, Lisa M.
Rodrigues, Margarida
Buxbaum, Sabine
Nilica, Bernhard
Singer, Susanne
Giesinger, Johannes M
Holzner, Bernhard
Virgolini, Irene
author_sort Gamper, Eva-Maria
collection PubMed
description PURPOSE: Health-related quality of life (HRQOL) in differentiated thyroid cancer (DTC) research has so far received little attention and available results are conflicting. We studied the HRQOL of radioiodine-naive DTC patients in comparison with the general population (GP), investigated the course of HRQOL up to 30 months after radioiodine remnant ablation (RAA) and sought to identify patient characteristics associated with HRQOL. METHODS: We analysed data from routine HRQOL monitoring at a nuclear medicine department. Between 2005 and 2013, a total of 439 thyroid cancer patients (all histologies) completed the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) at least once during their treatment at the department. We compared patients’ baseline HRQOL scores before RAA with scores from age-matched and sex-matched controls from the Austrian GP. We then determined the course of HRQOL over the 30 months after RAA and assessed the impact of the following clinical variables on HRQOL: method of thyroid-stimulating hormone (TSH) stimulation, histology (papillary vs. follicular) and disease stage. RESULTS: A total of 284 patients (mean age 48.3 years, SD 15.0 years; 71.6 % women; 80.7 % papillary type) with a baseline HRQOL assessment before RAA were available. We found clinically meaningful differences in the detriment in patients on almost all domains. These were largest for fatigue (23 points) and role functioning (25 points). Data from 241 patients (mean age 48.6 years, SD 15.9 years; 68.9 % women; 76.3 % papillary type) were included in the longitudinal analysis. Investigating the course of HRQOL, a significant improvement over time was found for role and emotional functioning, fatigue, pain, and dyspnoea. A range of HRQOL scores were improved in patients with exogenous TSH stimulation, but some scores both in patients with exogenous TSH stimulation and in those followed for 30 months, especially fatigue and role functioning, did not reach levels in the GP sample. CONCLUSION: Our results show that the favourable prognosis of DTC does not directly translate into good HRQOL in these patients. Persistent restrictions in regaining their normal daily life in terms of work and leisure highlight the importance of more detailed investigation of DTC patients’ wellbeing, support needs, and disease experience.
format Online
Article
Text
id pubmed-4480943
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-44809432015-07-02 Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme Gamper, Eva-Maria Wintner, Lisa M. Rodrigues, Margarida Buxbaum, Sabine Nilica, Bernhard Singer, Susanne Giesinger, Johannes M Holzner, Bernhard Virgolini, Irene Eur J Nucl Med Mol Imaging Original Article PURPOSE: Health-related quality of life (HRQOL) in differentiated thyroid cancer (DTC) research has so far received little attention and available results are conflicting. We studied the HRQOL of radioiodine-naive DTC patients in comparison with the general population (GP), investigated the course of HRQOL up to 30 months after radioiodine remnant ablation (RAA) and sought to identify patient characteristics associated with HRQOL. METHODS: We analysed data from routine HRQOL monitoring at a nuclear medicine department. Between 2005 and 2013, a total of 439 thyroid cancer patients (all histologies) completed the EORTC Quality of Life Questionnaire Core-30 (QLQ-C30) at least once during their treatment at the department. We compared patients’ baseline HRQOL scores before RAA with scores from age-matched and sex-matched controls from the Austrian GP. We then determined the course of HRQOL over the 30 months after RAA and assessed the impact of the following clinical variables on HRQOL: method of thyroid-stimulating hormone (TSH) stimulation, histology (papillary vs. follicular) and disease stage. RESULTS: A total of 284 patients (mean age 48.3 years, SD 15.0 years; 71.6 % women; 80.7 % papillary type) with a baseline HRQOL assessment before RAA were available. We found clinically meaningful differences in the detriment in patients on almost all domains. These were largest for fatigue (23 points) and role functioning (25 points). Data from 241 patients (mean age 48.6 years, SD 15.9 years; 68.9 % women; 76.3 % papillary type) were included in the longitudinal analysis. Investigating the course of HRQOL, a significant improvement over time was found for role and emotional functioning, fatigue, pain, and dyspnoea. A range of HRQOL scores were improved in patients with exogenous TSH stimulation, but some scores both in patients with exogenous TSH stimulation and in those followed for 30 months, especially fatigue and role functioning, did not reach levels in the GP sample. CONCLUSION: Our results show that the favourable prognosis of DTC does not directly translate into good HRQOL in these patients. Persistent restrictions in regaining their normal daily life in terms of work and leisure highlight the importance of more detailed investigation of DTC patients’ wellbeing, support needs, and disease experience. Springer Berlin Heidelberg 2015-03-13 2015 /pmc/articles/PMC4480943/ /pubmed/25771905 http://dx.doi.org/10.1007/s00259-015-3022-9 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Gamper, Eva-Maria
Wintner, Lisa M.
Rodrigues, Margarida
Buxbaum, Sabine
Nilica, Bernhard
Singer, Susanne
Giesinger, Johannes M
Holzner, Bernhard
Virgolini, Irene
Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
title Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
title_full Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
title_fullStr Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
title_full_unstemmed Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
title_short Persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
title_sort persistent quality of life impairments in differentiated thyroid cancer patients: results from a monitoring programme
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480943/
https://www.ncbi.nlm.nih.gov/pubmed/25771905
http://dx.doi.org/10.1007/s00259-015-3022-9
work_keys_str_mv AT gamperevamaria persistentqualityoflifeimpairmentsindifferentiatedthyroidcancerpatientsresultsfromamonitoringprogramme
AT wintnerlisam persistentqualityoflifeimpairmentsindifferentiatedthyroidcancerpatientsresultsfromamonitoringprogramme
AT rodriguesmargarida persistentqualityoflifeimpairmentsindifferentiatedthyroidcancerpatientsresultsfromamonitoringprogramme
AT buxbaumsabine persistentqualityoflifeimpairmentsindifferentiatedthyroidcancerpatientsresultsfromamonitoringprogramme
AT nilicabernhard persistentqualityoflifeimpairmentsindifferentiatedthyroidcancerpatientsresultsfromamonitoringprogramme
AT singersusanne persistentqualityoflifeimpairmentsindifferentiatedthyroidcancerpatientsresultsfromamonitoringprogramme
AT giesingerjohannesm persistentqualityoflifeimpairmentsindifferentiatedthyroidcancerpatientsresultsfromamonitoringprogramme
AT holznerbernhard persistentqualityoflifeimpairmentsindifferentiatedthyroidcancerpatientsresultsfromamonitoringprogramme
AT virgoliniirene persistentqualityoflifeimpairmentsindifferentiatedthyroidcancerpatientsresultsfromamonitoringprogramme